絞り込み

18364

広告

「Leuk Lymphoma[Journal]」の検索結果

11741件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis.

Development of a cell-line model to mimic the pro-survival effect of nurse-like cells in chronic lymphocytic leukemia.

Characteristics and outcome of patients with relapsed/refractory Hodgkin lymphoma following front-line escalated BEACOPP-based chemotherapy: a report from the Australasian Lymphoma Alliance.

Let-7b regulates the adriamycin resistance of chronic myelogenous leukemia by targeting AURKB in K562/ADM cells.

Improvement of therapy-induced myelodysplastic syndrome by infusion of autologous CD34-positive hematopoietic progenitor cells without chemotherapy.

Prognostic value of MRD monitoring based on copy numbers in Philadelphia chromosome positive acute lymphoblastic leukemia.

Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma.

Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study.

Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population.

Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy.

Refractory acquired angioedema in chronic lymphocytic leukemia.

Therapeutic vaccines for aggressive B-cell lymphoma.

Clinical characteristics, therapeutic management, and prognostic factors of adult COVID-19 inpatients with hematological malignancies.

Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma.

SIX6 is a TAL1-regulated transcription factor in T-ALL and associated with inferior outcome.

Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Clinical characteristics and survival of extranodal natural killer/T-cell lymphoma: a single-center 12-year retrospective analysis.

The influence of programmed cell death ligand 2 (PD-L2) expression on survival outcome and tumor microenvironment in diffuse large B cell lymphoma.

Identifying high-risk patients with natural killer/T-cell lymphoma undergoing autologous stem cell transplantation.

Modeling pediatric AML FLT3 mutations using CRISPR/Cas12a- mediated gene editing.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります